Briacell Therap (NASDAQ:BCTX) Short Interest Up 84.6% in May

Briacell Therap (NASDAQ:BCTX) was the recipient of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 867,761 shares, an increase of 84.6% from the May 14th total of 470,162 shares. Based on an average trading volume of 269,245 shares, the short-interest ratio is presently 3.2 days. Approximately 10.0% of the company’s shares are short sold.

Institutional Investors Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC bought a new stake in shares of Briacell Therap (NASDAQ:BCTX) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap as of its most recent filing with the SEC. 15.42% of the stock is currently owned by institutional investors.

Briacell Therap Stock Performance

Shares of NASDAQ:BCTX traded up $0.10 during midday trading on Monday, hitting $2.87. 33,380 shares of the company’s stock traded hands, compared to its average volume of 367,750. The company has a market cap of $24.97 million, a PE ratio of -0.12 and a beta of 1.21. The firm’s fifty day moving average price is $3.82 and its two-hundred day moving average price is $5.31. Briacell Therap has a twelve month low of $2.60 and a twelve month high of $32.40.

Briacell Therap (NASDAQ:BCTX) last announced its quarterly earnings results on Tuesday, June 9th. The company reported ($0.99) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

BCTX has been the topic of a number of research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. Wall Street Zen raised shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.